Dry and Wet Age-Related Macular Degeneration – Epidemiology – Middle East & Africa

Clarivate Epidemiology’s coverage of age-related macular degeneration (AMD) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of AMD for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we forecast the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.

Clarivate Epidemiology’s AMD forecast will answer the following questions:

• Of all people with AMD, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
• Of all people diagnosed with AMD, how many in each of the major mature pharmaceutical markets are drug-treated?
• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AMD over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 16 AMD patient populations, as follows:

• Total prevalent cases of AMD.
• Total prevalent cases of early AMD.
• Total prevalent cases of intermediate AMD.
• Total prevalent cases of late AMD.
• Total prevalent cases of wet AMD.
• Total prevalent cases of geographic atrophy.
• Total prevalent cases of dry AMD.
• Diagnosed prevalent cases of geographic atrophy.
• Diagnosed prevalent cases of wet AMD.
• Drug-treated prevalent cases by geographic atrophy.
• Drug-treated prevalent cases of wet AMD.
• Non-drug-treated prevalent cases by geographic atrophy.
• Non-drug-treated prevalent cases of wet AMD.

… and more (details available on request).

Note: Coverage may vary by country.